Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of March 2026, specifically reporting on a capital raise transaction announced on March 26, 2026, with an expected closing date of March 27, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.0 million.
- Securities Issued: 8,000,000 ordinary shares at an offering price of $0.50 per share.
- Warrants Issued:
- Series B Warrants: 8,000,000 warrants exercisable at $0.55 per share, expiring in 5 years.
- Series C Warrants: 8,000,000 warrants exercisable at $0.55 per share, expiring in 1 year.
- Placement Agent Fees: 7.0% of aggregate gross proceeds (reduced to 3.0% for certain mutually agreed investors).
- Expense Reimbursement: Up to $50,000 for legal and other expenses.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Offering Structure
The Company executed a Registered Direct Offering and a concurrent private placement. The ordinary shares were offered pursuant to a registration statement on Form F-3 declared effective on March 24, 2026. The warrants and shares issuable upon their exercise are not registered under the Securities Act of 1933 and are being offered under Section 4(a)(2) and/or Regulation D exemptions. The Company is required to file a registration statement on Form F-1 within 15 calendar days to register the shares issuable upon warrant exercise.
Restrictions, Risks, and Management Commentary
- Lock-Up Agreements: Directors and executive officers are restricted from selling shares or equivalents for 60 days following the closing date.
- Market Stand-Off: The Company is restricted from offering or selling ordinary shares or equivalents for 45 days post-closing without the Placement Agent's consent.
- Variable Rate Transaction Ban: The Company is prohibited from entering into variable rate transactions for six months following the closing date.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to inherent uncertainties and risks detailed in the Company's 2025 Form 20-F.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting fees and expenses.
- Confirm the filing and effectiveness of the Form F-1 registration statement for the warrant shares within the required 15-day window.
- Review the specific list of investors qualifying for the reduced 3.0% placement fee.
- Assess the impact of the 16,000,000 new warrants (Series B and C) on future dilution, given the $0.55 exercise price versus the $0.50 offering price.